Biotech has been at a low year-to-date, but traders believe the sector is going to make a comeback. » Read More
Highmark has gotten just a small fraction of the approximately $223 million it says the federal government owes it.
Theranos has informed authorities of its decision to issue corrected blood-test reports to doctors and patients, The Wall Street Journal reports.
From ninja-like "Infinity Burial Suits" to becoming part of a mushroom patch, there are some seriously cool disruptions happening to death, says VC Lisa Suennen.
Zika, the mosquito-borne virus, could reach Europe's borders as soon as late spring or this summer, a UN health agency warned Wednesday.
J&J's consumer brands and medical devices units are poised for growth following turnaround efforts, CEO Alex Gorsky says.
The Obama administration is finally giving employers rules for wellness programs that won’t violate privacy and discrimination regulations.
Capsule says its home-delivery prescription service will be faster and simpler for many consumers.
Citron's Andrew Left says he does not think Valeant shares will trade above $60 anytime soon.
Shortly after releasing its initial results, Perrigo revised its net loss figures to be lower than originally stated.
Since 2011, the percentage of Americans who lack health insurance has fallen by 6 percentage points.
Spending on children's health care grew annually by an average of 5.1 percent from 2010 to 2014, mainly due to price hikes.
A new study released Monday found that 45 percent of heart attacks in the United States are "silent" — the people having them don't realize.
Employers around the country say they are struggling to find workers who can pass a pre-employment drug test, The New York Times reports.
A campaign to raise California's cigarette tax by $2 a pack said it has collected enough signatures to qualify the proposal for the Nov. 8 ballot.
Valeant said on Monday it would make available to all hospitals in the U.S. an enhanced rebate program to reduce the price of Nitropress and Isuprel.
Pfizer will buy Anacor Pharmaceuticals in a deal valued at $5.2 billion, for access to Anacor's non-steroidal topical gel to treat eczema.
The case involves a man whose wife died of a lung cancer-related brain tumor after smoking the company's low-tar cigarettes.
Pfizer announced controls on the distribution of its products to ensure that none are used in lethal injections, the New York Times reports.
Allergan rose nearly 3 percent after Goldman Sachs released a very bullish note on the stock.
Intrexon is ready to fight the Zika virus and believes it will get approval to do so in the U.S., its CEO says.
Get the best of CNBC in your inbox